NCT03098589 2025-03-30
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
Celgene
Completed
Celgene
Rutgers, The State University of New Jersey
M.D. Anderson Cancer Center
University of Alberta
Taipei Medical University
Inje University
University of South Florida